DOW JONES25,766.64-1190.95 -4.42%
S&P 5002,978.76-137.63 -4.42%
NASDAQ8,566.48-414.30 -4.61%

Oppenheimer Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $62

Oppenheimer maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target from $52 to $62.

Benzinga · 01/08/2020 16:06

Oppenheimer maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target from $52 to $62.